NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
HDFC Securities Institutional Equities
India’s healthcare sector is poised for growth, with an expected steady 11-12% compound annual growth rate over the next five years, led by favorable macroeconomic factors such as healthcare infrastructure and a structural shift towards an organised market. Within this healthcare landscape:
the hospital segment has already undergone the capex phase (added bed capacity over FY14-19). It is now in the execution phase, focusing on improving occupancy and ARPOB, translating into a better margin. Going ahead, bed expansion and improving operating metrics will support growth/margins.
The Indian diagnostics market is in the recovery phase post-Covid and it is expected to see an 8-9% CAGR over the next four years. This growth will be led by volumes, price hikes in select tests, expansion of wellness services, and geographical expansion. Increasing competition and steep discounts from online peers are key challenges.
Retail pharmacy is poised for strong growth with an increasing market share of organised players.
We are initiating coverage with a Buy rating for Apollo Hospitals Enterprise Ltd. (target price of Rs 7,030) and Medplus Health Services Ltd. (target price of Rs 850), and an Add rating for Max Healthcare Institute (target price of Rs 900), DLPL (target price of Rs 2,700), and Metropolis Healthcare Ltd. (target price of Rs 2,010).
The near-term concern persists regarding the blanket price implementation as per the Clinical Establishment Act, which may impact profitability and the capex cycle.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Supreme Industries, Astral Shares Poised For Double-Digit Upside: JPMorgan Initiates 'Overweight'

.jpeg?rect=0%2C0%2C3500%2C1969&w=75)
Bharti Airtel Is A 'Buy' For These Analysts — Check Reason And Price Target

.png?rect=0%2C0%2C3500%2C1969&w=75)
'Hold' Berger Paints Shares Maintains Nirmal Bang; Awaits Better Entry Point— Check Target Price


Dixon Technologies Can Rally 33%, Says Motilal Oswal Maintaining 'Buy' — Check Target Price
